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SYNOPSIS
Trastuzumab and rituximab are genetically engineered
antibodies which are now available for the treatment of
metastatic breast cancer and non-Hodgkin’s lymphoma
respectively. The adverse effects of these drugs are mild
compared with conventional chemotherapy, but they
require intravenous infusion in a supervised setting.
Trastuzumab and rituximab are most effective when given
with chemotherapy rather than as a substitute for standard
therapies. Such combination therapy offers incremental
but significant clinical improvements. The challenge
remains to identify optimal antibody dosing schedules and
the cancer subtypes which best respond to these treatments.
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Introduction
The first monoclonal antibodies were generated, using
hybridoma technology, almost three decades ago. The hope
was that these ‘magic bullets’ would target cancer cells
without damaging normal cells thus offering a clear advantage
over conventional cancer treatments. Major trials using
genetically engineered antibodies to treat non-Hodgkin’s
lymphoma and breast cancer have now been completed and it
appears that the clinical utility of some antibodies has at last
been realised. The results from these trials have changed old
notions of the ideal therapeutic antibody. They show that
monoclonal antibodies are most effective when used in
combination with, rather than instead of, chemotherapy.
Mechanism of action of therapeutic
anticancer antibodies
Antibodies are large molecules (150 KiloDaltons). They consist
of a variable region, which binds specifically to a target
antigen, and a constant region, which mediates a variety of
effector functions such as cell-mediated killing and complement
activation.
In their native form, unconjugated antibodies have a wide
range of antitumour activities. Antibodies can directly influence
tumour cell growth by blocking a growth factor receptor or
they can cross link cell membrane antigens to deliver signals
that control the cell cycle or even induce cell death.
Alternatively, they can influence tumour growth indirectly by
activating host immune effector functions such as antibody-
dependent and complement-mediated cell cytotoxicity. Given
the diversity of actions of unconjugated antibodies, it is often
impossible to identify those specific actions which are operative
in a given individual.
Antibodies raised in mice (murine) have significant
disadvantages as therapeutic agents. They are immunogenic,
a feature which limits their repeated administration, and they
have poor cytotoxicity as their constant region does not
interact with human effector cells.
Molecular techniques now make it possible to transform
murine antibodies into human antibodies. A chimeric antibody
is generated by substituting a human constant region (usually
IgG1) for the murine constant region so that the new antibody
is 60% human and 40% murine (Fig. 1). A further step on from
a chimeric antibody is a humanised antibody (95% human and
5% murine). In this process the structural amino acids in the
variable region as well as in the constant region are replaced
by human sequences (Fig. 1). Only a small number of amino
acids directly responsible for binding to the antigen are retained
from the mouse antibody.
Coupling antibodies to cytotoxic agents such as drugs, toxins
and radionuclides potentially links the unique specificity of
antibodies with powerful tumouricidal activity. Despite the
theoretical advantage of such an approach, there are as yet few
practical examples of its implementation. One notable success
is the use of a humanised anti-CD33 antibody (gemtuzumab)
covalently linked to a derivative of a cytotoxic antibiotic,
calicheamicin. This drug, called gemtuzumab ozogamicin,
has shown activity in elderly patients with acute myeloid
leukaemia who are unsuitable for conventional chemotherapy.
Murine Chimeric Humanised
Fig. 1
The structure of a chimeric and humanised antibody
compared with its mouse counterpart. The red indicates
mouse, the grey represents human protein.
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Trastuzumab – breast cancer
Trastuzumab is a humanised antibody which targets the
HER2/neu receptor, a cell surface protein which is
overexpressed in a proportion of breast cancers. Original
reports suggested that HER2 was overexpressed in 20–30% of
breast cancers and therefore a significant number of women
would potentially benefit from trastuzumab. Unfortunately
this figure was an overestimate; overexpression is probably
closer to 10%.
Suitability for trastuzumab therapy is predicated on the accurate
identification of HER2 overexpression. This presents a
significant challenge as it requires specialised and expensive
techniques such as immunostaining and fluorescent in situ
hybridisation (FISH) analysis. Neither of these tests is perfect.
Trastuzumab is currently available in Australia for the treatment
of HER2 positive tumours under two circumstances:
• monotherapy in women who have received one or more
chemotherapeutic regimens for metastatic disease
• in combination with taxanes (such as paclitaxel) in women
who have not previously received chemotherapy for
metastatic disease.
Monotherapy
Approximately 15% of women with HER2 positive tumours
have an objective response to weekly intravenous
monotherapy.1 This response rate is comparable to that seen
with chemotherapy drugs such as paclitaxel (25%), docetaxel
(35%), vinorelbine (22%), 5-fluorouracil (25%) and
capecitabine (20%). While the incidence of serious toxicity is
probably lower with trastuzumab, it is difficult to draw
meaningful conclusions about the relative merits of each drug
as they have not been directly compared in a single study. With
regard to costs it is clear that drugs such as trastuzumab,
paclitaxel and docetaxel are many times more expensive than
capecitabine and 5-fluorouracil.
Combination therapy
As predicted by in vitro studies, there is considerable synergy
between trastuzumab and chemotherapy. As first-line treatment
for metastatic disease, the addition of trastuzumab to paclitaxel
increases the response rate (complete and partial) from 17% to
41%, the median time to disease progression from 3.0 months
to 6.9 months and the median survival from 20.3 to 25.1
months.2 The precise impact of trastuzumab on overall survival
may have been underestimated. A number of factors confound
this analysis, for example, patients who were randomised to
chemotherapy were permitted to receive trastuzumab
subsequently once their cancer progressed.
Importantly, the clinical advantages of trastuzumab were
obtained without additional negative effects on quality of life.
Most treatment adverse effects were attributable to the
chemotherapy. However, trastuzumab cannot be safely used
with all chemotherapy. There was an unexpectedly high
incidence of cardiac dysfunction (27% of patients) when the
drug was combined with anthracyclines.
On balance, it is reasonable to conclude that the combination
of trastuzumab and chemotherapy results in a modest
improvement in response rates and probably overall survival
in a very select group of women. As yet unresolved issues
include the necessity for weekly antibody infusions, the best
means of identifying women whose tumour growth is dependent
upon HER2 overexpression, and the true value of trastuzumab
in the adjuvant setting.
Rituximab – lymphoma
Rituximab was the first antibody to be approved by the US
Food and Drug Administration for the treatment of malignancy.
It is a chimeric antibody which binds strongly to the CD20
antigen found on normal mature B cells as well as on tumour
cells in nearly all B cell non-Hodgkin’s lymphomas.
Monotherapy
Low-grade lymphoma is a chronic illness usually requiring
intermittent, but long-term, treatment to control disease
symptoms. The listing of rituximab on the Pharmaceutical
Benefits Scheme has expanded the range of therapeutic options
for patients with low-grade lymphoma whose disease is not
responsive to alkylating agents. The evidence supporting the
use of rituximab was provided by an open label single arm
phase III study. In the 151 evaluable patients who had previously
received chemotherapy nine had complete responses and 67
had partial responses.3
Treatment with rituximab involves four infusions given at
weekly intervals. A number of patients have received further
courses of therapy with good effect.
Most patients experience fever, chills and rigors within two
hours of commencing the first infusion. The incidence of
infusion-related symptoms decreases to 40% with subsequent
infusions. Approximately 10% of patients develop serious
symptoms including immediate hypotension, bronchospasm
and rarely a late onset cytokine release syndrome characterised
by severe dyspnoea and hypoxia up to two days after the
infusion. Rituximab binds to normal B cells which are the
precursors of the immunoglobulin producing plasma cells.
Serum immunoglobulin levels can fall after treatment,
however this is not usually clinically significant.
In terms of relative therapeutic effect rituximab appears to
offer comparable efficacy, but with less toxicity than intensive
combination chemotherapy or drugs such as fludarabine. The
optimal schedule of administration remains a key unresolved
issue. Rituximab is detectable for three to six months following
a single course of therapy so it is possible that infrequent single
doses may provide maximum therapeutic effectiveness.
Combination therapy
About 30% of patients with non-Hodgkin’s lymphoma have
diffuse large B cell lymphoma, and more than half of these
patients are over 60 years old. For about 25 years the standard
treatment for this form of lymphoma has been a regimen of
cyclophosphamide, doxorubicin, vincristine and prednisone
(CHOP) given every three weeks for six months. Over the
years more complicated combinations have been tried, but
none have improved on the 30–40% cure rate observed with
CHOP. The results of combination therapy with rituximab and
CHOP have therefore sparked considerable interest.
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The addition of rituximab to CHOP significantly improved the
complete remission rate (75% versus 63%) and overall survival
at two years (70.2% versus 57.3%) in patients aged between 60
and 80 years.4 Importantly, these gains were made without
apparent increase in overall toxicity.
The apparent success with combination therapy cannot yet be
applied to all patients with lymphoma. Lymphoma is a
heterogenous disease and the responses to treatment are clearly
dependent upon a number of factors including the exact type
of lymphoma and the age of the patient. For instance, there are
currently no data supporting any role for the combination of
rituximab and chemotherapy in people under 60 years old.
The cost of treatment needs consideration. One cycle of
treatment with rituximab-CHOP costs approximately $4000
compared with $500 for CHOP alone. Another consideration
is the new data which show that increasing the frequency of
CHOP to fortnightly produces comparable improvements, in
overall survival and complete remission rates, to those seen
with rituximab-CHOP. Given these findings, and the cost of
rituximab, it will be important to establish the optimal number
of infusions, as well as the specific sub-group of patients for
whom this drug is truly beneficial.
Conclusion
Therapeutic antibodies have not revolutionised the management
of patients with cancer. However, the incremental gains
associated with the use of these drugs have cemented their
place in the clinical management of a select group of individuals.
Over the next few years the precise role of these and other
antibodies as adjuvant or first-line treatment for specific
diseases will become apparent.
E-mail: r.ward@garvan.unsw.edu.au
R E F E R E N C E S
1. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S,
Fehrenbacher L, et al. Multinational study of the efficacy and safety of
humanized anti-HER2 monoclonal antibody in women who have
HER2-overexpressing metastatic breast cancer that has progressed after
chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
(sponsored trial)
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,
et al. Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med
2001;344:783-92. (sponsored trial, randomised trial)
3. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS,
Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody
therapy for relapsed indolent lymphoma: half of patients respond to a four-
dose treatment program. J Clin Oncol 1998;16:2825-33. (sponsored trial)
4. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al.
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med
2002;346:235-42. (sponsored trial, randomised trial)
Conflict of interest: none declared
Self-test questions
The following statements are either true or false
(answers on page 151)
9. Trastuzumab is only indicated for women with breast
cancers which overexpress the receptor HER2.
10. A serious adverse reaction to rituximab may not
develop until two days after the infusion.
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Choice Companion: Aged Care.
Adelaide: Australian Medicines Handbook;
2003.
218 pages. Price $50, students $45, plus
postage.
Shanthi Kanagarajah, Geriatrician, Melbourne
The Companion is intended for use in conjunction with the
Australian Medicines Handbook (AMH), the well-known and
highly valuable drug formulary. It aims to assist those working
in aged care, especially in residential facilities. The nearly
pocket sized volume with a ring binding is easy to handle and the
cover is probably resistant to contamination by bodily fluids.
The text itself is organised into common clinical problems in
the aged care setting, with dementia and other neurological
conditions heading the list. Following the instructions inside
the front cover, I used the index to trace my way through
typical clinical questions. Each topic is subdivided into
consistent subheadings that include diagnostic issues and
non-drug issues. The subsections on ‘evidence’ are a neat way
of giving credence to the book’s assertions.
There are useful summaries on conditions that one meets much
more often in nursing homes than in textbooks of medicine –
restless legs syndrome, managing stroke risk in people with
advanced morbidity, and (not) crushing or splitting tablets.
Several practice points and warnings are highlighted as call-outs,
an effective device to focus one’s attention to key messages.
The brevity of the work does present difficulties, for example
there is no evidence section under insomnia. In Parkinsonism
the problem of a poor clinical response to dopaminergic
therapy is clearly stated, but the difficulty of existing postural
hypotension (such as in multisystem atrophy) being aggravated
by the drugs, is only hinted at. I found the inclusion of the
section on irritable bowel syndrome puzzling, given that it
may be ‘less common in older than in younger people’ and
‘convincing evidence for the efficacy of drug treatments… is
lacking’. Disabling stroke is a difficult management problem
in nursing homes and hostels and a section on the therapeutics
of spasticity would have been useful.
The Companion reasonably succeeds in its aim of assisting the
busy aged care worker at the bedside. Doctors, nurses and
pharmacists, particularly those doing medication reviews, should
find this extremely useful. It is a ‘first of its kind’ in Australia.
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